In accordance with the patient's informed consent and appropriate review by the IRB (Institutional Review Board), glioblastoma patient-derived cells were obtained from a patient undergoing surgery at the Samsung Medical Center (Seoul, Korea). The tumor sample was classified as glioblastoma based on the pathologist's examination and according to the World Health Organization criteria. Within 1 h following surgical resection, the tumor was mechanically and enzymatically dissociated into single cells. Before injection of the single cells into mice, glioblastoma patient-derived cells were briefly maintained in NBE (Neuronal Basal Medium) neurosphere culture medium consisting of Neurobasal-A medium (Invitrogen, Carlsbad, CA, USA) supplemented with glutamine (2 mM, Invitrogen, Carlsbad, CA, USA), penicillin (100 units/ mL, Invitrogen), streptomycin (100 mg/mL, Invitrogen, Carlsbad, CA, USA), recombinant human basic fibroblast and epidermal growth factors (100 ng/mL each, R&D Systems, Minneapolis, MN, USA), and N2 and B27 supplements (0.5 × each, Invitrogen, Carlsbad, CA, USA).
Design of the anti-miR oligomer: Anti-miR-10b
Anti-miR oligomer was a kind gift from Regulus Therapeutics. The anti-Let-10b oligomer sequence is 5ʹ-AATTCGGTUCTACAGGGTA-3ʹ.
Anti-miR treatment in vitro
To evaluate intracellular transfer efficiency of antimiR in glioblastoma patient derived cell in vitro, GBM04T cell was plated at 1 × 10 5 cells/2 mL culture medium per well in a 6-well plate. GBM04T cell was treated with antimiR-10b (0-100 µM) without any chemical reagents in the culture medium. 48 h after the treatment, anti-miR10b treated cell was harvested for target gene expression analysis by qRT-PCR. 
miR-10b expression analysis by qRT-PCR

Immunohistochemistry quantification
To analyze anti-miR-10b distribution in the mouse brain in vivo, we produced a serial of 4 µm thick paraffin sections and were subjected for immunohistochemical staining after anti-miR-10b administration. For immunohistochemistry, primary antibody against anti-miR (supplied form Regulus therapeutics, 1:1000) was used and the resultant sections were pathologically confirmed for tumor phenotype and specific immunostaining. The positive cells were counted and analyzed by HistoQuest 3.0 software (Tissue Gnostics, Vienna, Austria).
Statistics
To analyze statistical comparisons of tumor regression and the significance of differences in overall survival. we measured the Mantel-Cox log-rank test and Kaplan-Meier graph represented using Prism5 software. All data are presented as mean ± S.E.M and significance level of p < 0.05 was used for all tests. Figure S1 : Antisense oligomers mediate differential expression of target genes in glioblastoma patientderived cell. (A) qRT-PCR analysis of hHMGA2 mRNA expression in anti-Let7-treated (10-100 µM, for 48 h) glioblastoma patientderived cells (GBM04T). (B) qRT-PCR analysis of hIGFBP2 mRNA expression in anti-Let7-treated (10-100 µM, for 48 h) GBM04T cells. (C) qRT-PCR analysis of hLIN28B mRNA expression in anti-Let7-treated (10-100 µM, for 48 h) GBM04T cells. Data are presented as means ± S.E.M. *p < 0.05, **p < 0.01, and ***p < 0.001 compared with the control.
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